Von Hippel–Lindau (VHL) disease is a hereditary cancer syndrome predisposing to renal cell carcinoma (RCC), typically considered more indolent than sporadic RCC. The ‘3 cm rule’ has guided ...

"Imaging using [⁸⁹Zr]Zr-girentuximab has the potential to change clinical practice in renal cell carcinoma," write the study authors. HealthDay News — ⁸⁹Zr-labeled monoclonal antibody ...

Clear cell RCC is the most common histologic subtype of malignant tumors of the kidney. This histology accounts for 75% of renal masses that are evaluated. 7,8 Clear cell RCC derives from the proximal ...

For decades, researchers have been seeking a therapy to improve outcomes for patients with clear cell renal cell carcinoma who underwent a nephrectomy. Postsurgical immunotherapy significantly ...

Stage 2 ccRCC is localized, with tumors larger than 7 cm but no lymph node or distant metastasis involvement. Diagnosis involves imaging, laboratory tests, and occasionally biopsy, with surgery as the ...

Select patients with oligometastatic ccRCC might be managed with a period of metastasis-directed therapy alone. Serial metastasis-directed radiation therapy may delay systemic therapy in clear cell ...

Renal cell carcinoma (RCC) is one of the 10 most commonly diagnosed solid tumors. Most RCCs are histologically defined as clear cell, comprising approximately 75% of diagnoses. However, the remaining ...

Adjuvant everolimus does not improve recurrence-free or overall survival in patients with papillary and chromophobe subtypes of non–clear cell renal cell carcinoma (RCC) and is associated with higher ...

Belzutifan, a hypoxia-inducible factor 2α inhibitor, showed clinical activity in clear-cell renal-cell carcinoma in early-phase studies. In a phase 3, multicenter, open-label, active-controlled trial, ...